NGM Biopharmaceuticals Dividend
Dividend criteria checks 0/6
NGM Biopharmaceuticals hat in der Vergangenheit keine Dividende gezahlt.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.3% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$1.71 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Mar 02Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year
Jan 26
NGM Bio gives update on 2021 plans and data timeline
Jan 12NGM Bio prices $125M share offering
Jan 06NGM Biopharmaceuticals proposes $100M public offering
Jan 04Stability and Growth of Payments
Fetching dividends data
Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von NGM in der Vergangenheit stabil geblieben ist.
Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von NGM gestiegen sind.
Dividend Yield vs Market
| NGM Biopharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (NGM) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Pharmaceuticals) | 2.3% |
| Analyst forecast in 3 Years (NGM) | 0% |
Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von NGM im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.
Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von NGM im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.
Earnings Payout to Shareholders
Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von NGM, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.
Cash Payout to Shareholders
Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da NGM keine Ausschüttungen gemeldet hat.